EEG-centred computational biomarkers and complementary physiological signals for mild cognitive impairment and early Alzheimer’s disease: A systematic review 2005–2025
- 1Corresponding author.
- 2Auckland University of Technology, Private Bag 92006, Auckland 1142, New Zealand
Abstract
Background: Electroencephalography (EEG) provides a portable approach to assessing mild cognitive impairment (MCI) and early Alzheimer’s disease (AD), while sleep and autonomic signals may offer complementary physiological information. The validation quality of these computational biomarkers remains uncertain. Objective: To systematically evaluate signal-processing approaches, candidate biomarkers, computational models, and risk of bias in an EEG-centred evidence base for MCI and early AD, with complementary physiological studies considered as secondary evidence. Methods: Following PRISMA 2020 guidelines, we systematically reviewed 118 studies (2005–2025), comprising 113 direct EEG studies, two studies of polysomnography-derived sleep architecture, and three complementary non-EEG studies, and appraised risk of bias using a PROBAST-informed framework. Results: Recurring EEG findings included spectral slowing, reduced signal complexity, altered event-related potentials, and disrupted functional connectivity. Across 120 extracted performance rows, the median reported accuracy was 93.41%, and values above 95% were common. The proportion classified as High overall risk ranged from 38.1% to 69.5% across operational sample-size thresholds and was 22.0% when sample size was excluded. Twenty-two studies were at high risk of data leakage, only one reported external validation, and longitudinal evidence remained limited (9 studies; none used time-to-event modelling). Conclusions: The EEG-centred literature presents a performance paradox: high reported accuracy coexists with data-leakage concerns, limited external validation, and little longitudinal evidence. Future studies should use design-specific sample-size planning, strict subject-level separation, external validation, and longitudinal outcome modelling to establish clinically reliable computational biomarkers.
Related
- Plasma Neurofilament Light Chain as a Complementary Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.
- Multimodal Machine Learning Approaches to Detect Attention-Deficit/Hyperactivity Disorder (ADHD) Using Physiological and Behavioural Biomarkers: A Systematic Review.
- Complement C4b and factor B in astrocyte-derived exosomes as novel biomarkers for amnestic mild cognitive impairment
- Walking speed and propulsion asymmetry as distinct diagnostic biomarkers of gait impairment: Towards precision rehabilitation after stroke
- Gastrodin alleviates mild cognitive impairment and Alzheimer’s disease via candidate targeting of ACHE, S1PR5, SERPINE1, and TOP2A: an integrative computational and cellular study
BibTeX
@article{truong2026eegcentred,
title = {{EEG-centred computational biomarkers and complementary physiological signals for mild cognitive impairment and early Alzheimer’s disease: A systematic review 2005–2025}},
author = {Ha Truong and Victoria Kvasniak and Gautam Anand and Anubha Kalra and Farhaan Mirza and Kerri Spooner and Sruthy Krishna},
journal = {Neuroscience Informatics},
year = {2026},
month = oct,
doi = {10.1016/j.neuri.2026.100298},
url = {https://doi.org/10.1016/j.neuri.2026.100298},
note = {CC BY},
}
RIS
TY - JOUR
TI - EEG-centred computational biomarkers and complementary physiological signals for mild cognitive impairment and early Alzheimer’s disease: A systematic review 2005–2025
AU - Ha Truong
AU - Victoria Kvasniak
AU - Gautam Anand
AU - Anubha Kalra
AU - Farhaan Mirza
AU - Kerri Spooner
AU - Sruthy Krishna
PY - 2026
DA - 2026/10/30
JO - Neuroscience Informatics
DO - 10.1016/j.neuri.2026.100298
UR - https://doi.org/10.1016/j.neuri.2026.100298
AB - Background: Electroencephalography (EEG) provides a portable approach to assessing mild cognitive impairment (MCI) and early Alzheimer’s disease (AD), while sleep and autonomic signals may offer complementary physiological information. The validation quality of these computational biomarkers remains uncertain. Objective: To systematically evaluate signal-processing approaches, candidate biomarkers, computational models, and risk of bias in an EEG-centred evidence base for MCI and early AD, with complementary physiological studies considered as secondary evidence. Methods: Following PRISMA 2020 guidelines, we systematically reviewed 118 studies (2005–2025), comprising 113 direct EEG studies, two studies of polysomnography-derived sleep architecture, and three complementary non-EEG studies, and appraised risk of bias using a PROBAST-informed framework. Results: Recurring EEG findings included spectral slowing, reduced signal complexity, altered event-related potentials, and disrupted functional connectivity. Across 120 extracted performance rows, the median reported accuracy was 93.41%, and values above 95% were common. The proportion classified as High overall risk ranged from 38.1% to 69.5% across operational sample-size thresholds and was 22.0% when sample size was excluded. Twenty-two studies were at high risk of data leakage, only one reported external validation, and longitudinal evidence remained limited (9 studies; none used time-to-event modelling). Conclusions: The EEG-centred literature presents a performance paradox: high reported accuracy coexists with data-leakage concerns, limited external validation, and little longitudinal evidence. Future studies should use design-specific sample-size planning, strict subject-level separation, external validation, and longitudinal outcome modelling to establish clinically reliable computational biomarkers.
SN - 2772-5286
ER -